Charles A Parsons

US Patent:

20070172507, Jul 26, 2007

Filed:

Jan 26, 2006

Appl. No.:

11/340071

Inventors:

Paul Zupkas - San Diego CA, US
Charles Parsons - San Diego CA, US

International Classification:

A61K 31/737
A61K 31/728
A61K 31/727
A61K 31/24

US Classification:

424423000, 514054000, 514056000, 514536000

Abstract:

Transluminal drug delivery method and device embodiments may include a urethral suppository formulated to treat diseases of the urethra and surrounding organs by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse affects on the glucosaminoglycan (GAG) barrier by the suppository may be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.

US Patent:

61712981, Jan 9, 2001

Filed:

Mar 11, 1998

Appl. No.:

9/041475

Inventors:

David G. Matsuura - Escondido CA
Walter Dean Gillespie - La Mesa CA
John Patrick Greelis - Carlsbad CA
Charles Lowell Parsons - La Jolla CA
Mikxay Sirivong - San Diego CA
Paul F. Zupkas - San Diego CA

Assignee:

Situs Corporation - Solana Beach CA

International Classification:

A61K 922

US Classification:

6048911

Abstract:

A drug-infusing device is implanted into a body cavity such as a bladder. The device is implanted in an uninflated, low profile state. After insertion into the body cavity, the device is filled with a substance, such as a drug, and assumes an increased profile. After the device is filled, it is allowed to float freely within the body cavity. Alternatively, the device can be tethered to a wall of the body cavity. The device delivers the drug at a controlled rate over an extended period of time. In order to deliver the drug at a controlled rate, the device preferably has a pressure-responsive valving member. The flow resistance of the valving member is responsive to the pressure at which the drug is stored within the infusing device. The resistance of the valving member decreases as the pressure within the infusing device decreases, thereby providing a resultant controlled flow rate.

US Patent:

61834610, Feb 6, 2001

Filed:

Sep 14, 1999

Appl. No.:

9/395415

Inventors:

David G. Matsuura - Escondido CA
Walter Dean Gillespie - La Mesa CA
John Patrick Greelis - Carlsbad CA
Charles Lowell Parsons - La Jolla CA
Mikxay Sirivong - San Diego CA
Paul F. Zupkas - San Diego CA

Assignee:

Situs Corporation - Solana Beach CA

International Classification:

A61M 3100

US Classification:

604502

Abstract:

A drug-infusing device is implanted into a body cavity such as a bladder. The device is implanted in an uninflated, low profile state. After insertion into the body cavity, the device is filled with a substance, such as a drug, and assumes an increased profile. After the device is filled, it is allowed to float freely within the body cavity. Alternatively, the device can be tethered to a wall of the body cavity. The device delivers the drug at a controlled rate over an extended period of time. In order to deliver the drug at a controlled rate, the device preferably has a pressure-responsive valving member. The flow resistance of the valving member is responsive to the pressure at which the drug is stored within the infusing device. The resistance of the valving member decreases as the pressure within the infusing device decreases, thereby providing a resultant controlled flow rate.